UK markets close in 4 hours 21 minutes

CureVac N.V. (CVAC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.5300+0.0900 (+3.69%)
At close: 04:00PM EDT
2.6000 +0.07 (+2.77%)
Pre-market: 07:02AM EDT

CureVac N.V.

Friedrich-Miescher-Strasse 15
Tübingen 72076
Germany
49 7071 9883 0
https://www.curevac.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees904

Key executives

NameTitlePayExercisedYear born
Mr. Pierre Kemula B.Sc.MD, CFO & Member of Management Board585.01kN/A1975
Dr. Malte Greune Ph.D.COO, Member of Management Board & MD454.97kN/A1965
Dr. Ulrike Gnad-Vogt M.D., Ph.D.Senior VP & Area Head of Oncology373.55kN/A1973
Dr. Alexander Zehnder M.B.A., M.D.CEO, MD & Member of Management BoardN/AN/A1970
Dr. Myriam Mendila M.D.Chief Development Officer, MD & Member of the Management BoardN/AN/A1966
Dr. Sarah FakihVice President Corporate Communications & Investor RelationsN/AN/AN/A
Mr. Marco Rau L.L.M., Ph.D.General CounselN/AN/AN/A
Mr. Thorsten SchullerHead of Corporate CommunicationsN/AN/AN/A
Slavica Stevanovic-HeckHead of Human ResourcesN/AN/AN/A
Dr. Patrick BaumhofSenior Vice President of TechnologyN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Corporate governance

CureVac N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.